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Tumor budding and laminin5-γ2 
in squamous cell carcinoma of the external 
auditory canal are associated with shorter 
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Abstract 
Squamous cell carcinoma (SCC) of the external auditory canal (EAC) is rare, usually presents at an advanced stage, and 
is a more aggressive tumor with poor prognosis. The University of Pittsburgh TNM staging system commonly used 
in prognostication is not perfect, and more accurate biomarkers predicting prognosis are needed. Tumor budding is 
an established negative prognostic factor at the invasive front in colorectal cancer. Moreover, immunohistochemi-
cal studies showed that laminin 5-γ2 (Ln5-γ2) is expressed at the invasive front in tumor or tumor budding cells. We 
assessed the prognostic significance of tumor budding and Ln5-γ2 expression by performing Ln5-γ2 immunohisto-
chemistry and evaluated the degree of tumor budding in pre-treatment biopsy specimens, and investigated their 
correlations to clinicopathological parameters in patients with SCC of the EAC. Patients whose tumors had high bud-
ding grade and Ln5-γ2 expression had significantly shorter survival times. Budding grade was significantly correlated 
with Ln5-γ2 expression. Multivariate analysis revealed that high budding grade predicted poorer prognosis regardless 
of disease stage. Our results suggested that budding grade and Ln5-γ2 expression can be used as indicators of poor 
prognosis in patients with SCC of the EAC.
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Background
Squamous cell carcinoma (SCC) of the external audi-
tory canal (EAC) is an aggressive malignancy with a poor 
prognosis. The reported incidence is less than six cases 
per million per year, accounting for 0.2  % of all tumors 
of the head and neck, with a reported 5-year disease-spe-
cific survival ranging from 19 to 48 % (Moffat et al. 2000; 
Bacciu et  al. 2013; Prasad et  al. 2014; Masterson et  al. 
2014). Because of the rarity of this tumor, it has been 
difficult for any single institution to analyze the clinical 
data and formulate an optimal evaluation and treatment 
strategy. Another impediment to the study of SCC of the 
EAC is the lack of a universally accepted staging system 
(Bacciu et  al. 2013; Prasad et  al. 2014; Masterson et  al. 
2014; Nakagawa et al. 2006). Currently, there is no recog-
nized stand-alone American Joint Committee on Cancer 
(Chicago, IL, USA) or International Union Against Can-
cer (Geneva, Switzerland) staging system for SCC of the 
EAC (Prasad et  al. 2014). A revised University of Pitts-
burgh (Pittsburg, PA, USA) staging system was proposed 
in the year 2000 (Moody et al. 2000). This system is the 
classification tool that is commonly used for prognosis 
and treatment decisions in patients with SCC of the EAC 
(Bacciu et  al. 2013; Prasad et  al. 2014; Masterson et  al. 
2014; Nakagawa et al. 2006; Moody et al. 2000). However, 
this tool does not correctly classify every patient (Prasad 
et  al. 2014; Mazzoni et  al. 2014); although the number 
is small, there are some patients with tumors that recur 
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locally despite their categorization as low-risk and, con-
versely, patients with longer survival times despite their 
categorization as high-risk, based on the TNM system 
(Prasad et al. 2014). The failure of TNM staging to serve 
as a reliable prognostic system for patients with inter-
mediate-stage tumors may be overcome by considering 
morphologic, molecular, or treatment-related factors to 
stratify patients more precisely into different risk catego-
ries. Thus, search for biomarkers that reflect the biologic 
characteristics of SCC of the EAC and treatment out-
come prediction is crucial (Marioni et al. 2012, 2013).
Tumor budding/sprouting is a histological feature at 
the invasive front of a tumor and an established nega-
tive prognostic factor when present in resected colorectal 
cancer and preoperative rectal cancer biopsy specimens 
(Morodomi et al. 1989; Hase et al. 1993; Ueno et al. 2002; 
Zlobec and Lugli 2010; Mitrovic et al. 2012; Rogers et al. 
2014; Satoh et al. 2014). The concept of tumor budding/
sprouting was first described in the 1950s by Imai, who 
postulated that the presence of “sprouting” at the inva-
sive edge of a carcinoma indicates a more rapid tumor 
growth rate (Imai 1960). Tumor budding is thought to 
represent an active invasive form of cancer; specifically, 
it is the isolation and mobilization of cancer cells from a 
main tumor mass during the early stages of tumor inva-
sion (Hase et al. 1993). Tumor cells that have undergone 
the epithelial-to-mesenchymal transition (EMT) are indi-
cated histologically by the presence of tumor budding 
(Mitrovic et  al. 2012). Tumor budding is predictive of 
lymph node metastasis, vascular and lymphatic invasion, 
non-responsiveness to neoadjuvant chemo-radiotherapy, 
distant metastasis, local recurrence, and a poor progno-
sis (Morodomi et al. 1989; Ueno et al. 2002; Koike et al. 
2008; Brown et al. 2010; Sarioglu et al. 2010; Zlobec and 
Lugli 2010; Luo et  al. 2012; Mitrovic et  al. 2012; Rog-
ers et al. 2014; Satoh et al. 2014). A high level of tumor 
budding/sprouting is associated with a poorer progno-
sis in several human solid cancers, including some types 
of SCC, e.g., esophageal SCC (Koike et  al. 2008; Brown 
et  al. 2010), laryngeal carcinoma (Sarioglu et  al. 2010), 
and nasopharyngeal carcinoma (Luo et  al. 2012). For 
head and neck SCC, the importance of invasion pattern 
for prognosis has been extensively addressed since seven-
ties (Willen et al. 1975; Anneroth et al. 1987; Bryne et al. 
1992, 1998). The studies have shown that it is not the dif-
ferentiation grade but the invasion pattern that is impor-
tant for assessment of clinicopathological aggressiveness. 
Particularly, the invasion pattern classified as Grade 
or Score 4, which referred to neoplasms with a marked 
diffuse, widespread cellular invasion of the neoplasm in 
single neoplastic cells or in small groups of cells, corre-
sponds to tumor budding mentioned herein (Anneroth 
et al. 1987). More recently, a non-cohesive invasive front 
is reported to be an indicator of metastasis in the SCC 
of the ear auricle, which is known to metastasize to the 
regional lymph nodes more frequently than SCC at other 
sites (Clark et al. 2010).
Previously, our laboratory showed that laminin 5-γ2 
(Ln5-γ2) has a role in invasion of cutaneous SCC (Hama-
saki et al. 2011). We also reported that even in the early 
stages of SCC of the EAC, diffuse expression of Ln5-γ2 
is associated with a poor prognosis (Nakagawa et  al. 
2013). Laminin 5, a heterotrimer composed of three dif-
ferent Laminin chains (α3-, β3-, γ2-), is the major com-
ponent of the basement membrane in most adult tissues 
(Nguyen et al. 2000). One of the chains, Ln5-γ2, is a spe-
cific marker for invasive tumors because it is frequently 
expressed as a monomer in several types of malignant 
tumors (Nguyen et al. 2000; Koshikawa et al. 2008). Sev-
eral immunohistochemical studies have found that Ln5-
γ2 expression is observed exclusively in the cytoplasm 
of budding cells at the invasive front in many types of 
human cancers, such as colon, and breast cancer, and 
SCC of the esophagus, cervix, and skin (Pyke et al. 1995; 
Yamamoto et al. 2001; Hamasaki et al. 2011).
To our knowledge, the degree of tumor budding in SCC 
of the EAC has not yet been described. The aim of this 
study was to assess the degree of tumor budding and its 
correlation to Ln5-γ2. We also performed an immuno-
histochemical analysis of Ln5-γ2 in pre-treatment ear 
cancer biopsy specimens to investigate the prognostic 
significance of Ln5-γ2 expression.
Methods
Patients
We retrospectively reviewed clinicopathological data for 46 
patients with primary SCC of the EAC, for whom the pre-
treatment tissue specimens were available, and who were 
treated by the same strategy at the Department of Oto-
rhinolaryngology, Kyushu University Hospital (Fukuoka, 
Japan) from January 1998 to March 2006 and at the Depart-
ment of Otorhinolaryngology, Fukuoka University Hospi-
tal (Fukuoka, Japan) from April 2006 to December 2014. 
Patients who underwent chemotherapy or radiation prior 
to biopsy, patients for whom specimens were not available, 
or patients who failed to follow our treatment plan, were 
excluded from the study. As long as the provisions for main-
taining patient anonymity are followed, tissues from biopsy 
samples can be used for research purposes per a standard 
treatment agreement with Kyushu University and Fukuoka 
University Hospitals. The study protocol was approved by 
the Institutional Review Board (The Ethics Committee) of 
Kyushu University (No. 26-185) and Fukuoka University 
(No. 12-7-13) Hospitals. Clinical stage was determined 
using the staging protocol proposed by the University 
of Pittsburgh (Moody et  al. 2000). Before treatment, the 
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extent of disease was estimated in all patients by physical 
examination and imaging studies [Computed tomography 
(CT), and magnetic resonance imaging (MRI)]. The inva-
sion of the canal wall of the internal carotid artery, jugular 
bulb, otic capsule, and dura mater was determined by CT, 
and the extension to the soft tissue, petrous apex, middle 
ear, mastoid, temporomandibular joint, and parotid gland 
was distinguished by MRI. CT and MRI scans were rou-
tinely conducted every 6 months, for 3 years, after therapy. 
After 3 years, CT and MRI were performed annually. The 
surgical or post-irradiation scarring was often indistin-
guishable from residual or recurrent disease. An absence 
of any signs of enlargement of a space-occupying lesion, 
was designated as “no evidence of disease”. The follow-up 
period for the complete series ranged from 4 to 66 months 
(median, 34 months).
Tissue samples and immunohistochemistry (IHC)
Biopsy specimens were fixed in 10 % formalin and pro-
cessed into paraffin blocks. Paraffinized tissue blocks 
were sectioned (4-μm thickness), deparaffinized, and 
hydrated in descending alcohol dilutions. For anti-
cytokeratin (CK) antibody staining, sections were 
immersed in 3 % hydrogen peroxide in water for 10 min 
at room temperature (RT) to block endogenous peroxi-
dase activity, and heated in 10  mM ethylenediamine-
tetraacetic acid (EDTA) buffer (pH 8.0) in a microwave 
(700  W) for 10  min to retrieve epitopes before stain-
ing. For anti-Ln5-γ2 antibody staining, sections were 
immersed in 0.05  % protease XXIV (Sigma-Aldrich, 
Tokyo, Japan) for 15  min at RT to block endogenous 
peroxidase activity. The sections were incubated with 
anti-human CK monoclonal antibody (AE1/AE3, Dako; 
1:200), or anti-human Ln5-γ2 monoclonal antibody 
(D4B5, Temecula, CA, USA; 1:200), for 1  h at RT (for 
CK), or for 1 h at 37 °C (for Ln5-γ2). The sections were 
then washed in Tris-buffered saline (TBS) and incu-
bated for 30 min at RT with EnVision reagent conjugated 
horseradish peroxidase (Dako; for CK), or Histofine 
reagent conjugated to alkaline phosphatase (Nichirei 
Bioscience; for Ln5-γ2). Immunoreactive proteins were 
visualized with 3,3′-diamino-benzidine (DAB; Dako; for 
CK), or New Fuchsin substrate kit (Nichirei Bioscience, 
Tokyo, Japan; for Ln5-γ2), followed by counterstain-
ing with Mayer’s hematoxylin (for CK), or methylgreen 
(for Ln5-γ2). The stained sections were evaluated semi-
quantitatively by two independent observers who were 
blinded to the clinical data.
Grading for tumor budding/sprouting
Based on the Japanese Classification of Colorectal Carci-
noma (JCCC) (Rectum JSfCotCa 2013), we defined tumor 
budding/sprouting as a cancer cell nest consisting of five or 
fewer cells that infiltrated the interstitium at the invasive 
margin of the cancer. After selecting an area in which bud-
ding/sprouting was most intensive, the buds were counted 
in a field measuring 0.785  mm2 through a 20×  objective 
lens (WHK 10×  ocular lens; Olympus, Tokyo, Japan). 
Depending on the number of buds, we used the modified 
grading system proposed by Satoh et al. (2014) for estima-
tion of tumor budding: Grade 0, no budding (Fig.  1a, e); 
Grade 1, 1–4 buds (Fig. 1b, f); Grade 2, 5–9 buds (Fig. 1c, g); 
Grade 3, ≥10 buds (Fig. 1d, h). We used this grading system 
to evaluate tumor budding in H&E- (Fig.  1a–d) and CK-
immunostained (Fig. 1e–h) sections. The degree of tumor 
budding was classified as low grade or high grade, corre-
sponding to 0–9 (grades 0, 1, and 2) or ≥10 budding foci 
(grade 3) in one field, respectively, according to Ueno et al. 
(2002). This grading system has been proven to be have 
prognostic significance, is easily applied, and is frequently 
used in tumor budding studies (Mitrovic et al. 2012).
Immunohistochemical analysis of Ln5‑γ2
Immunoreactivity for Ln5-γ2 was observed as cyto-
plasmic staining in carcinoma cells. The immunostain-
ing result was considered to be negative if <10 % of the 
tumor cells were stained. In specimens considered to 
have a positive result, the tumor staining pattern was 
assessed as marginal (Fig.  2a) or diffuse (Fig.  2b), and 
was quantitated on a scale from 1 to 4 based on the per-
centage of positively-stained tumor cells. The scale was 
as follows: 1+, 10–24  % positive (Fig.  2c); 2+, 25–49  % 
positive (Fig. 2d); 3+, 50–74 % positive (Fig. 2e); and 4+, 
75–100 % positive (Fig. 2f ). Each tumor was then classi-
fied as low-expression (1+  and 2+) or high-expression 
(3+ and 4+).
Statistical analysis
The relationships between several clinicopathological 
parameters and the results of budding assessments and 
IHC were evaluated using the Student’s-t test for contin-
uous variables, and Fisher’s exact test for categorical var-
iables. Disease-specific survival curves were plotted by 
the Kaplan–Meier method, and P values were calculated 
using the log-rank test. A univariate analysis was per-
formed for each clinicopathological parameter. Multi-
variate analysis and the Cox proportional-hazard model 
were used to determine the independent prognostic fac-
tors. A P value <0.05 was considered statistically signifi-
cant. All data analyses were conducted with JMP10.0.2 
(SAS Institute Inc., Cary, NC, USA) for Windows.
Results
Clinical and histopathological findings
Table  1 summarizes the clinicopathological character-
istics of 46 patients [25 male and 21 female; age range, 
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Fig. 1 Hematoxylin-eosin staining of SCC of the EAC showing tumor budding/sprouting (a–d) and cytokeratin immunohistochemistry (CK-IHC) for 
tumor budding/sprouting (e–h) at the invasive front. Inset in a, e shows absence of tumor budding; budding grade 0, the others shows presence of 
tumor budding; b, f shows budding grade 1, c, g shows budding grade 2, and d, h shows budding grade 3
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38–86 years (mean = 62.5)]. The median follow-up period 
was 34.6 months (range 4–66 months). The TNM stages 
for a majority of tumors was stage IV [25 (54.3 %)]. The 
proportion of distant metastasis was low (4.3 %), similar 
to that reported in previous studies (Moffat et  al. 2000; 
Moody et  al. 2000; Nakagawa et  al. 2006; Bacciu et  al. 
2013; Prasad et al. 2014; Masterson et al. 2014). The pro-
portion of patients in which the cancer had spread to the 
lymph nodes was 21.7 %, slightly higher than that in previ-
ous studies (ranging from 10 to 15 %) (Moffat et al. 2000). 
Because all the metastatic nodes were in an advanced 
stage according to the staging protocol proposed by Uni-
versity of Pittsburgh, we considered N1, N2a, and N2b 
as N+. The presence of lymphovascular invasion could 
not be assessed because of the size of the biopsy speci-
mens. Lateral temporal bone resection was achieved in 15 
cases, subtotal temporal bone resection was achieved in 
16 cases, and 15 cases received only chemo-radiotherapy. 
Of the 31 (69.6 %) patients who underwent surgery, post-
operative data was available for 21 (65.6 %) patients and 
Fig. 2 Immunohistochemical analysis of Ln5-γ2 expression in SCC of the EAC. a Marginal expression pattern. b Diffuse expression pattern. The 
expression level is scored as 1+ to 4+ based on the percentage of positively stained tumor cells. c 1+: 0–24 %, d 2+: 25–49 %, e 3+: 50–74 %, f 4+: 
75–100 %
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6 (29  %) patients had postoperative local recurrence. Of 
these 21 patients, 18 (85.7  %) had received neoadjuvant 
chemo-radiotherapy. Of these patients, we assessed the 
effect of therapy using surgical tissue specimens, accord-
ing to the General Rules for Clinical Studies on Head and 
Neck Cancer (Cancer JSfHaN 2012). The effect of ther-
apy was classified as one case (5.6 %) with a grade 0, one 
(5.6  %) with a grade 1, 9 (50.0  %) with a grade 2, and 7 
(38.9 %) with a grade 3, response.
Tumor budding in pre‑treatment biopsy samples
Tumor budding was first assessed in H&E-sections 
(Fig. 1a–d). However, assessment was sometimes difficult 
because of the presence of reactive fibroblasts or mac-
rophages in the stroma surrounding the invasive front. 
Therefore, we assessed budding carcinoma cells based on 
CK-IHC data (Fig.  1e–h), according to a method previ-
ously reported by Satoh et al. (2014).
The results for the budding data grading indicated that 
13 (28.3 %) patients had tumors graded as 0, 20 (43.5 %) 
patients had grade 1 tumors, 6 (13.0 %) patients had grade 
2 tumors, and 7 (15.2  %) patients had grade 3 tumors. 
Thirty-nine (84.8 %) patients had low budding grade and 
7 (15.2 %) patients had high budding grade tumors. There 
was no significant association between tumor budding 
and the clinicopathological parameters (Table 1).
Expression of Ln5‑γ2 and clinicopathological correlations
Immunoreactivity for Ln5-γ2 was observed in all SCC 
of the EAC cases in this study. All tumors demonstrated 
cytoplasmic and membranous staining. The expres-
sion level was as follows: 20 patients (43.5 %) as 1+, 17 
Table 1 Clinicopathological features of  46 patients with  SCC of  EAC and  their correlation to  tumor growth pattern 
and budding grade
M male, F female, MCF middle cranial fossa
All Tumor budding Budding grade
n (%) Absent
13 (28.3)
Present
33 (71.7)
P value Low
39 (84.8)
High
7 (15.2)
P value
Mean age [years, (sd)] 62.5 (±11.4) 65.0 (±3.1) 61.5 (±1.9) 0.358 63.1 (±1.8) 59.3 (±0.4.3) 0.426
M:F 21:25 (46:54) 8:5 (62:38) 17:16 (52:48) 0.743 21:18 (54:46) 4:3 (57:43) 1.000
T
 T1 1 (2.2)
 T2 12 (26.1) 4 (30.8) 9 (27.3) 11 (28.2) 2 (28.6)
 T3 9 (19.5)
 T4 24 (52.2) 9 (69.2) 24 (72.7) 1.000 28 (84.8) 5 (71.4) 1.000
N
 N0 36 (78.3) 11 (84.6) 25 (75.8) 31 (79.5) 5 (71.4)
 N+ 10 (21.7) 2 (15.4) 8 (24.2) 0.700 8 (20.5) 2 (28.6) 0.636
M
 M0 44 (95.7) 13 (100) 31 (94.0) 38 (97.4) 6 (85.7)
 M+ 2 (4.3) 0 (0) 2 (6.0) 1.000 1 (2.6) 1 (14.3) 0.284
TNM stage
 Stage I 1 (2.2)
 Stage II 10 (21.7) 4 (30.8) 7 (21.2) 10 (25.6) 1 (14.3)
 Stage III 10 (21.7)
Stage IV 25 (54.4) 9 (69.2) 26 (78.8) 0.702 29 (74.4) 6 (85.7) 1.000
Differentiation
 Well 28 (60.9) 7 (53.8) 21 (63.6) 26 (66.7) 2 (28.6)
 Moderate 15 (32.6) 6 (46.2) 9 (27.3) 11 (28.2) 4 (57.1)
 Poor 3 (6.5) 0 (0) 3 (9.1) 0.309 2 (5.1) 1 (14.3) 0.157
Recurrence 21
 Free 15 (71.4) 4 (80.0) 11 (68.8) 15 (78.9) 0 (0)
 Recurrence 6 (28.6) 1 (20.0) 5 (31.2) 1.000 4 (21.1) 2 (100) 0.071
Effect of therapy 18
 Grade 0–2 11 (61.1) 1 (25.0) 10 (71.4) 9 (60.0) 2 (66.7)
 Grade 3 7 (38.9) 3 (75.0) 4 (28.6) 0.245 6 (40.0) 1 (33.3) 1.000
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(37.0  %) as 2+, 6 (13.0  %) as 3+, and 3 (6.5  %) as 4+. 
Thirty-seven (80.4  %) patients had tumors with high 
expression of Ln5-γ2 (1+, 2+). Nine (19.6  %) patients 
had low levels (3+, 4 +) of Ln5-γ2 expression. The Ln5-
γ2 expression patterns showed significant associations 
with age, advanced TNM stage (stage III and IV), and 
poor tumor differentiation (P = 0.0161, P = 0.0439, and 
P = 0.0200, respectively). High Ln5-γ2 expression levels 
were significantly associated with older age (P = 0.0224).
Tumor budding and Ln5‑γ2 expression
The results for the relationships between tumor bud-
ding and Ln5-γ2 expression are summarized in Table 2. 
There was a significant correlation between presence 
of tumor budding and high Ln5-γ2 expression levels 
(P = 0.0444). High budding grade correlated significantly 
with both a diffuse Ln5-γ2 expression pattern and high 
Ln5-γ2 expression levels (P  =  0.0458 and P  =  0.0016, 
respectively).
Patients survival
Disease-specific survival curves, sorted by the pres-
ence of tumor budding (Fig. 3a), budding grade (Fig. 3b), 
and the patterns (Fig.  3c) and levels (Fig.  3d) of Ln5-γ2 
expression were analyzed. The patient group with high 
tumor budding grades had significantly shorter survival 
times (P = 0.0007), but there was no statistically signifi-
cant difference between the groups in terms of the pres-
ence of tumor budding (P = 0.4055). The patient groups 
with a diffuse Ln5-γ2 expression pattern and high Ln5-γ2 
expression levels also had significantly shorter survival 
times (P = 0.0337 and P = 0.0079, respectively).
We also analyzed disease-specific survival in cases 
with only advanced stages (stage III and IV) of SCC of 
the EAC, sorted into groups based on the budding grade 
(Fig.  4a) and Ln5-γ2 expression levels (Fig.  4b). The 
patient groups with high budding grades and high Ln5-γ2 
expression levels had significantly shorter survival times 
(P = 0.0027 and P = 0.0484, respectively), even when the 
analysis was restricted to only those cases with advanced 
stage disease.
Univariate and multivariate analyses of clinicopatho-
logical predictors of disease-specific survival in these 
cases of SCC of the EAC were also performed. The results 
indicated that advanced age, patients treated without sur-
gery and high budding grades predicted poorer disease-
specific survival (Table  3). The high budding grade was 
an independent prognostic factor for poorer disease-
specific survival in patients with stage III and IV cancer 
(P = 0.010) (Table 3).
Discussion
To the best of our knowledge, this study was the first to 
assess tumor budding/sprouting by grade in SCC of the 
EAC samples. We found that high budding grade was 
significantly correlated with poor prognosis in patients 
with SCC of the EAC. The results of a multivariate analy-
sis indicated that high budding grade was an independ-
ent poor prognostic factor even in cases with advanced 
stage disease, although the number of patients analyzed 
was small particularly when considering the subgroups 
for statistical analysis (e.g. 7 patients with high budding 
grade). We also analyzed Ln5-γ2 expression levels, which 
have been documented in the literature as being associ-
ated with tumor budding (Pyke et al. 1995; Sordat et al. 
2000; Nabeshima et  al. 2006). The Ln5-γ2 expression 
level was significantly associated with tumor budding and 
budding grade. High Ln5-γ2 expression was also signifi-
cantly associated with shorter disease-specific survival.
Tumor budding/sprouting is a poor prognostic indica-
tor in several types of SCCs (Koike et  al. 2008; Zlobec 
and Lugli 2010; Brown et al. 2010). In the head and neck 
SCC, the tumor frequently shows higher grade of cellu-
lar dissociation at the invasive front than the remaining 
areas of the tumor, and grading of the invasive tumor 
front or margins is an independent prognostic factor in 
Table 2 Association of tumor budding and Ln5-γ2 expression
Ln5-γ2 Laminin 5-γ2
All
n (%)
Tumor budding P value Budding grade P value
Absence
13 (28.3)
Presence
33 (71.7)
Low
39 (84.8)
High
7 (15.2)
Ln5-γ2 expression pattern 46
 Marginal 35 (76.1) 10 (76.9) 25 (75.9) 32 (82.1) 3 (42.9)
 Diffuse 11 (23.9) 3 (23.1) 8 (24.1) 1.000 7 (17.9) 4 (57.1) 0.045
Ln5-γ2 expression level
 Low 37 (80.4) 13 (100) 24 (72.7) 35 (89.7) 2 (28.6)
 High 9 (19.6) 0 (0) 9 (27.2) 0.044 4 (10.3) 5 (71.4) 0.001
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Fig. 3 Kaplan–Meier survival curve relating to absent or present of tumor budding (a), budding grade (b), Ln5-γ2 expression pattern (c), and Ln5-γ2 
expression level (d) in the pre-treatment biopsy specimens from all cases in this study
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multivariate survival analysis (Bryne et al. 1992, 1998). 
In our study, most of the patients with tumor budding 
had shorter disease-specific survival times. On the 
contrary, among the patients with early stage disease 
(stage I and II), those with no tumor budding survived 
until the end of the follow-up period (66 months). Sev-
eral reports have described the relationships between 
clinicopathological parameters and tumor budding. 
Morodomi et  al. (1989) reported that tumor budding 
may be a prelude to lymphatic invasion. Koike et  al. 
(2008) reported that tumor budding correlates signifi-
cantly with lymph node metastasis, lymphatic and ves-
sel invasion, and intramural metastasis in SCC of the 
esophagus. Similarly in the auricular SCC, Clark et  al. 
(2010) reported that a non-cohesive invasive front is 
an indicator of lymph node metastasis. However, in our 
study, regional lymph node status was not significantly 
associated with tumor budding. The small number and 
proportion (21.7  %) of cases with lymph node metas-
tasis included in our study might have contributed to 
these differences.
Expression of Ln5-γ2 in budding cells is associated 
with focal under-expression of the E-cadherin-β-catenin 
complex in colorectal carcinoma (Nabeshima et al. 2006). 
The presence of tumor budding is considered to rep-
resent the EMT, a process frequently associated with 
increased expression of molecules relevant to tumor 
invasion, such as matrix metalloproteinases and Ln5-
γ2 in tumor cells, and stimulation of the Wnt signaling 
pathway (Zlobec and Lugli 2010). One study found that 
there is a link between Ln5-γ2-mediated budding activ-
ity and decreased cell–cell adhesion (Nabeshima et  al. 
2006). Similarly, our study revealed that Ln5-γ2 expres-
sion was significantly correlated with budding grade. The 
patient groups with high Ln5-γ2 expression levels had a 
significantly shorter survival time, regardless of the dis-
ease stage. These results indicated that there was an asso-
ciation between higher Ln5-γ2 expression and a poor 
prognosis.
Conclusion
In conclusion, tumor budding may be an adverse prog-
nostic factor that can help stratify patients into more 
meaningful risk groups than TNM staging alone, and 
more importantly, has a potential to guide clinical deci-
sion-making. For example, low budding grade enabled 
us to sort the patient groups into those with better prog-
nosis even in cases of advanced stage diseases. The treat-
ment of patients with advanced-stage SCC of the EAC 
includes performing an extended en bloc temporal bone 
resection, which leaves the patients with a functional and 
a cosmetic deficit. Our results indicated that tumor bud-
ding could allow us to perform less invasive surgery for 
patients with low budding grade tumors. Additionally, 
tumor budding can be evaluated with relative ease during 
a routine pathological examination. Because of the strong 
correlation between Ln5-γ2 expression and tumor bud-
ding, we can use immunohistochemical analysis of Ln5-
γ2 as an alternative or concurrent parameter when tumor 
budding cannot be assessed in the biopsy specimen. (e.g., 
when the sample is too small or does not including the 
stroma). Although biological or clinical malignancy of 
tumors depends on not only invasiveness but also pro-
liferative ability of tumor cells, multivariate analysis 
in this study showed the mode of invasiveness is more 
important for survival than tumor size, stage, and differ-
entiation in SCC of the EAC. Further studies are now in 
practice in our laboratory to examine the molecular fac-
tors and mechanisms of tumor budding.
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